Recently, several improvements of traditional PCR techniques have facilitated the amplification of significantly longer DNA target sequences. Here we report an improved method for amplification of entire human papillomavirus (HPV) genomes. Using rTth DNA polymerase, XL (PerkinElmer, Foster City, CA), and the accompanying XL PCR buffer system, we have successfully amplified 8-kb genomes from -10 copies of input reference strain HPV16 DNA. This long PCR (LPCR) method was subsequently used to amplify the entire HPV16 genome from clinical specimens. The fidelity with which the rTth DNA polymerase XL amplifies target sequences under our chosen amplification conditions was estimated by partial sequencing of cloned LPCR products generated from cloned reference strain HPV16 genomes. A region spanning the HPV16 E6, E7, and part of the E1 open reading frames (ORFs) was sequenced in 29 clones. A total of 33 nucleotide substitutions were observed in the 23.5 kb sequenced. This corresponds to an error frequency of -one error per 700 bases. Finally, LPCR methods were used to amplify entire, novel HPV genomes from clinical specimens. LPCR primer pairs were designed for amplification of seven potentially novel HPV types. Amplicons of -8 kb were generated from five of the seven HPV types targeted. One of the LPCR-generated novel genomes, CP141, was subsequently cloned and a partial sequence was determined.
T h e ability of PCR to produce large quantities of DNA from very small amounts of genetic material has revolutionized molecular biology. (1 ' 2) The impact of PCR technology is probably best exemplified in genome mapping and sequencing. (3) Although PCR can be performed with relative ease, the size of the amplification products that can reliably be generated have been generally limited to -3-4 kb. (4) Recently, important alterations in amplification conditions have been identified that allow effective amplification of longer DNA targets. (s'6) The modified conditions for long PCR (LPCR) involve changes of the standard PCR buffer and cycling parameters together with a two-polymerase system that includes a polymerase activity and a 3'--~ 5' exonuclease activity. (s'6) Using LPCR protocols, ~<42 kb of the bacteriophage k genome, 22 kb of human genomic DNA, and 16.3 kb of the human mitochondrial genome have been successfully amplified. (s-7)
The use of a two-polymerase system including proofreading activity facilitates the amplification of much longer targets but may additionally influence 3Corresponding author. E-MAIL cwheeler@medusa.unm.edu; FAX (505) 277-8572.
the fidelity of the amplification/s) The reaction conditions used and the resultant fidelity during the amplification reaction are critical to determining the value of LPCR applications. As reviewed by Eckert and Kunkel, the observed error frequencies for Thermus aquaticus (Taq)-based PCR, in the absence of proofreading activity, can range from approximately one error per 363 nucleotides (3x10 -3) to one error per 5411 nucleotides (2x10-4), depending on the reaction conditions used. (8) Using LPCR technology we have recently developed a model system to allow effective amplification of the entire 7.9-kb human pappilomavirus type 16 (HPV16) genome. (9) HPVs are implicated as one of the causative agents in the etiology of cervical dysplasia and cervical cancer. (1°-1z) The study of the natural history and the classification of HPVs has been hampered owing to the lack of efficient in vitro culture systems for these viruses. Utilization of LPCR technology to study other papillomaviruses could greatly facilitate classification and characterization of known and potentially novel HPV genomes.
Here we report improved amplification of HPV target genomes present in cloned and clinical material and demonstrate a rapid protocol for the cloning of LPCR products. Moreover, we present an assessment of the fidelity with which the rTth DNA polymerase XL system amplifies its target sequences and, finally, STEWARI ET AL.
how LPCR technology can be used for the isolation of entire, novel HPV genomes.
MATERIALS AND METHODS

Samples and Preparation of DNA
Cervicovaginal lavages (13A4) were screened previously for specific HPV DNA types. (is) Ten samples that were strongly positive by HPV16 oligonucleotide hybridization, and two HPV-negative samples were chosen for LPCR analysis. Crude digestion was performed as described previously/Is) DNA was purified further using a standard phenol/ chloroform/isoamyl alcohol method, with mixing by inversion rather than vortexing to minimize DNA shearing.
Clinical specimens (crude proteinase digests) screened previously for the presence of potentially novel HPV sequences were obtained from investigations perforlned at the University of New Mexico, Albuquerque. (~6) DNA from these specimens was prepared as described previously. O6'17) Specimens designated ISXX were all obtained from the recently reported International Biological Study of Cervical Cancer (IBSCC). (18'19) GenBank accession numbers are as follows:  IS039,  U12481;  CP6108,  U12478;  CP141, U12476; CP8061, U12479;  MM9, U12491; MM7, U12489; MM4,  U12488. Clone ppH16, the entire HPV16 genome cloned into a single BamHI site in a pBR322 vector, (2°,21) was generously provided by Dr. E.-M. de Villiers (DKFZ Papillomavirus Reference Center, Heidelberg, Germany).
PCR Primers and Amplification
Abutting primers were designed juxtaposing the unique BamHI site for the HPV16 model system. (9) For the potential novel HPVs (16'18,z2) , abutting primers were designed juxtaposing restriction endonuclease (RE) sites present in the MY09/MY11 L1 fragments (23'24) that would potentially represent unique RE sites within the complete genomes once isolated. The selection of RE sites and primer locations was facilitated by sequence comparisons to other closely related HPV genomes. All primers contained Y-terminal sequences to permit regeneration of the juxtaposed RE site and a "clamp" of two to five guanines at the extreme 5' end to facilitate subsequent RE digestion and cloning. Unique RE sites were included at the 5' end of the HPV16 model system primers for directional cloning. The lengths of the primers varied between 22 and 35 bases. Individual primer pairs were selected to have balanced melting temperatures (Tm) that ranged between 65°C and 79°C as determined with Oligo 4.0 (National Biosciences, Plymouth, MN). Sequences of all oligonucleotides used for LPCR amplification are shown in Table 1 The thermal cycling conditions included a manual hot start (2s), which entailed withholding the Mg(OAc)2 until the reaction mixture had reached 80°C; an initial denaturation step at 94°C for 10 sec; 35-40 cycles in which each cycle consisted of 15 sec at 94°C, 1 min at 62°C, and 4-6 min at 68°C; and a final extension at 72°C for 10 min. All amplifications were performed in a Perkin- Elmer GeneAmp PCR System 9600, using MicroAmp tubes.
Cloning and Sequencing of LPCR Products
The LPCR products were subjected to electrophoresis in 0.8%-1% low melt or regular agarose gels containing ethidium bromide (EtBr). DNA fragments were visualized under long-wavelength (300 nm) UV light, and the bands of correct sizes (-8 kb) were excised from the gel. The DNA was isolated from the agarose using Gelase (Epicentre Technologies, Madison, WI), as recommended by the manufacturer, and ligated to the pGEM-T vector (Promega, Madison, WI). Bacterial colonies that contained recombinant plasmids were identified by cz-complementation screening. (26, 27) Selected colonies were grown in 2-ml cultures, and plasmids were isolated using a crude alkaline denaturation method essentially as described by Bimboim et al/2s'29) Bacterial cells, grown overnight in LB medium, were pelleted by low speed centrifugation. Cell pellets were resuspended in 300 !11 of 50 mM Tris-HCI, 10 mM EDTA, containing 100 ~tg/ml of RNase A. Three hundred microliters of 200 mM NaOH containing 1% SDS was added to the resuspended cells, whereupon they were gently mixed and incubated at room temperature for S min to lyse the bacterial cells. Finally, 3.0 M KOAc at pH 5.5 (300 lxl) was added, and the lysed bacterial cells were incubated on ice to precipitate chromosomal DNA. Cell debris and precipitated DNA were pelleted by centrifugation (14,000g) at room temperature for 15 min, and the supernatant was removed promptly. Plasmid DNA was precipitated by addition of 0.7 volumes of isopropanol to the supernatant, mixed by inversion, and pelleted by centrifugation (14,000g) at room temperature for 30 min. The DNA pellet was washed briefly in 70% EtOH, air-dried, and resuspended in 50 ~tl of deionized water.
RE digestion with BamHI (HPV16) and HindlII (CP141) of selected clones was used to confirm the presence of an intact 8-kb insert.
Cloned LPCR products were sequenced by the dideoxy termination method (s°) using aSS-labeled dATP and 
Restriction Endonuclease Analysis of CP141
Digests with different REs were carried out as described by the manufacturer (New England Biolabs, Inc., Beverly, MA). The enzymes used are described in Figure 5 (see below). The resulting DNA fragments were separated by electrophoresis in 0.8-2% agarose gels. Physical mapping of cleavage sites followed standard protocols.
RESULTS
Sensitivity in a HPV16 Model System
In a previous report we described a model system for amplification of the entire HPV16 reference genome cloned into a pBR322 vector. (9) The detection limit in this system was -1000 copies of linearized input DNA. This LPCR system was used to amplify the entire HPV16 genome directly from cervicovaginal larages that were previously positive for HPV16 DNA based upon PCR amplification of the 450-bp MY09/MY11 L1 fragment. (zs) The sensitivity of this model system, when applied directly to these clinical specimens, was low with only 2 of 21 cervicovaginal lavages producing the expected 7.9-kb HPV16 LPCR product.
To increase the sensitivity of the LPCR system, we have altered these previously reported conditions. By reducing the reaction volume (50 vs. 100 ~tl), prolonging the extension time (6 vs. 4 min), and increasing the number of amplification cycles (40 vs. 35), we obtained higher yields of amplified products. We also found that increasing the concentration of rTth polymerase XL from 0.5 to 1 unit per 50-~d reaction increased specific amplification product yields significantly. Using this modified protocol, we detected -10 copies of cloned HPV16 input DNA (Fig. 1A) . Application of this protocol and the inclusion of a very gentle phenol extraction step for sample preparation facilitated the successful amplification of fulllength circular HPV16 genomes from 10 of 10 cervicovaginal lavages (Fig. 1B) . LPCR product yields from the lavage amplifications were also improved by linearizing the circular DNA genome via BamHI restriction (Fig. 1C) . Although we achieved RE-verified 8-kb products from 10 of 10 clinical samples, the reaction specificity was quite variable between samples and among replicates (see Fig. 1C ). Nonspecific amplicon species range in size from -100 to 6500 bp. Similar background was seen from amplification of a circular HPV dimer that was regenerated by ligation of HPV plasmid inserts. Linear targets at concentrations >1000 copies were observed to yield two products (3.2 and 5.5 kb) that are produced from internal mispriming sites predicted from the HPV16 reference sequence. No other nonspecific amplification was observed with <50,000 copies of linearized HPV-conraining plasmid target or with HPV-negative lavages (data not shown). In all cases, the 7.9-kb target remained the predominant product. Preamplification specimen dilution, BamHI linearization, rTth DNA polymerase XL concentration reduction, and amplification using fewer cycles decreased but did not eliminate the nonspecific amplification. The extent to which any combination of the above improved specificity was sample dependent.
Fidelity During LPCR
Knowing that DNA polymerases can introduce errors during PCR-based amplification of target sequences, we wanted to assess the error frequency of our LPCR system. A commercial kit for T/A cloning was used to isolate LPCR products amplified from the HPV16 model system (cloned reference strain HPV16 DNA). from these clones were subjected to sequence analysis. Figure 3 shows that 11 of 29 clones contained no errors in the sequenced region (-1 kb). Eight clones contained one error, and 10 clones contained two errors or more. None of the clones contained more t h a n five errors in the region sequenced. In the clones with m a n y errors (e.g., clones F and J in (Fig. 3 ). This type of substitution was detected in 5 of the 33 errors found (15%). Only one base substitution was found at the same position (A ~ G, position 446) in two different clones (F and Z in Fig. 3 ).
Amplification and Cloning of Novel HPV Genomes
LPCR methods established in the HPV16 model system were subsequently applied to the amplification of entire novel HPV genomes. The expected error frequency determined in our HPV16 model system (one error per 700 bases, or <0.2%) was predicted to be adequate for characterization of novel HPV genomes. We selected seven potential novel HPV genomes for further study: CP141, CP6108, CP8061, IS039, PAP238 (MM9), PAP291 (MM7), and W13B (MM4). (16'18'22) One to three abutting primer pairs, with balanced melting temperatures, were designed for each of these potential novel HPVs. All primer pairs are located in the MY09/MY11 fragm e n t of the L 1 0 R F . The sequences of the LPCR primers are shown in Table 1 . Three cervical specimens from different patients containing CP141 sequences were tested using LPCR conditions as described in Materials and Methods. Primer pair 141HP/HN produced an 8-kb LPCR product from one of these specimens, 60224C (Fig. 4) . We did not detect any products of this size in the other two specimens examined. In all three specimens a similar pattern of smaller nonspecific amplicons, ranging in size from 1 to 4 kb, was detected. These nonspecific products were detected only in amplifications from clinical specimens. Cloned, supercoiled CP141 genome (see below) produced a single, 8-kb band after amplification under similar conditions (data not shown). No amplification products were observed using primer pair 141BP/BN with the three specimens tested.
The primer pair 6108BP/BN was tested for amplification of a potential CP6108 genome in three samples obtained from one patient, 61085V (vulvar), 61085C (cervical), and a cervicovaginal lavage specimen, 61085L. Only the vulvar specimen produced an 8-kb LPCR product that was barely visible following EtBr staining. By decreasing the concentration of Mg(OAc) 2 (1.0 vs 1.1 raM), the yields of the amplification product increased slightly, although the band intensity remained low (data not shown). Also, by increasing the concentration of the rTth XL buffer (1.1 vs 1.0×), the yields of the CP6108 product were slightly increased (Fig. 4) . The non- FIGURE 2 Generation, cloning, and analysis of LPCR products from HPV specimens. Abutting LPCR primers A and B were designed in the MY11-MY09 region of the novel HPV genomes. Amplification was performed using these primers as described in Materials and Methods. Complete 8-kb LPCR products were gel purified, cloned into a pGEM-T vector, and analyzed further using RE-based methods and sequencing analysis.
specific amplification of the CP6108BP/ BN primer pair was generally very low and appeared as a smear (Fig. 4) . Two specimens, IS039 and IS215 containing IS039 sequences, were tested for LPCR amplification of entire IS039 genomes utilizing three different primer pairs, IS39AN/AP, IS39NN/NP, and IS39SN/SP. One of these specimens, IS039, produced an 8-kb product with primer pairs IS39AN/AP and IS39NN/ NP. When the expected 8-kb genome was generated, we also observed abundant background bands that varied in size from 0.5 to 7 kb (Fig. 4) . No 8-kb amplification products were observed using primer pair IS39SN/SP with these specimens.
Seven specimens, IS601, IS780, IS461, C009, $214, $271, and $391, were subjected to LPCR amplification of entire PAP238 (MM9) genomes using the primer pair 238AEN/EP. Only one of these specimens, IS780, produced the targeted 8-kb amplification product. This amplification product was barely visible following EtBr staining (data not shown).
Using primer pairs W13BNN/NP, we tested six clinical specimens, W13B142, W13B385/389, W13B26018, IS887, IS766, and IS1016, for amplification of 8-kb HPV genomes. No amplification products of the expected 8-kb size were detected. An additional primer pair, IS39SN/SP, was applied to the same group of specimens and an 8-kb product was generated from W13B385/398 (Fig. 4) .
We did not detect 8-kb LPCR products from any specimens using the primer pairs 8061BP/BN, 8061BglN/ BglP, and 291BP/BN, although optimization experiments were not attempted with these primer pairs.
The five potentially novel HPV genomes that produced an 8-kb amplification product using our LPCR system were subsequently subjected to T/A cloning using the pGEM-T vector (see Fig. 2 for an outline of the entire procedure). We succeeded in cloning only the CP141 LPCR product using this technique. A total of 10 recombinant bacterial colonies from the CP141 pGEM-T ligation were analyzed. Five of these contained an insert of the anticipated 8-kb size when analyzed using RE digestion with HindlII. Three of the CP141 clones, CP141-3, CP141-6, and CP141-7, were analyzed further by RE digestion. All three clones exhibited identical RE digestion patterns with the exception of clone CP141-7 that had a restriction fragment length polymorphism (RFLP) when digested with BstNI. A physical map of the complete CP141 genome was constructed and is shown in Figure 5 .
Several CP141 clones were subjected to partial sequence analysis using primers derived from the pGEM-T vector, pGEM-F and pGEM-R. Sequence analysis revealed that an additional adenine had been added to the 3' end of the cloned LPCR products; this addition was necessary for successful T/A cloning. In the sequenced L1 region around the HindIII cloning site, CP141 shares 81% of its base pairs with HPV39 DNA. The resulting amino acid sequence located within the 3' part of the L10RF spanned from amino acids 310-501 (numerically oriented from the first amino acid of the ORF) in the sequenced CP141 clones. Alignment to the L10RF of HPV39 identified 28 of 191 (14.7%) amino acids that were different in CP141 compared See facing page for legend.) ._a. to HPV39 (Fig. 6 ). Conserved residues common to all genital papillomaviruses (24) were also conserved in our isolate of CP141 (Fig. 6) . One amino acid difference, an alanine substituted for a valine at position 444 was observed in our isolate compared to the published CP141 sequence. (16) The alanine at this position has been observed previously in another CP141 isolate in our laboratory (32) and in the LVX160 MY09/MY11 L1 fragment sequence. (33) Subsequent to these determinations this HPV genome was designated as HPV70 (E.-M. de Villiers, pets. comm.). The three LPCR products successfully amplified from IS039, W13B, and CP6108 were additionally subjected to RE digestion-based cloning techniques. The LPCR products from IS039, W13B, and CP6108 were digested with AfllI, ScaI, and BamHI, respectively. Analysis of the RE digests in 1% agarose gels revealed 8-kb products suggesting that a single RE site for each selected enzyme was present in the targeted HPV genomes. The digested products were subsequently ligated to a similarly restricted vector. Competent cells were transformed, and several (>200) colonies were screened. No clones with the expected 8-kb insert were detected for any of the LPCR products.
DISCUSSION
We have demonstrated that LPCR methods can be applied to the successful amplification of previously characterized as well as potentially novel HPV genomes directly from crude preparations of clinical specimens. It is likely that these methods will subsequently facilitate the isolation of other complete viral genomes.
Although linearization via BamHI restriction of circular HPV genomes present in lavage specimens improved LPCR product yields, our results suggest that the nicking that occurs during preparation of the nucleic acid and during thermal cycling creates a sufficient quantity of the relaxed form of the HPV DNA molecules to allow amplification of the full-length genomes. This observation is consistent with previous reports that supercoiled DNA cannot be heat denatured (34) and that the amplification rate with linearized DNA templates is significantly better than that with supercoiled templates. °s) Because PCR requires strand separation using high heat denaturation (94°C), only linear or relaxed circle forms of the HPV DNA can serve as the templates for amplification. RE-mediated "nicking" of the DNA circle relaxes the supercoil, thus increasing the effective concentration of HPV DNA by causing a rise in the proportion of HPV templates suitable for amplification.
Our results also suggest that the nonspecific amplification products obtained with the HPV16 genome from either lavages or purified cloned DNA are generated from the circular and/or supercoiled form of the HPV genome, as linear HPV and non-HPV targets have failed to generate background products with the exception of the 3.2-and the 5.5-kb products described above. BamHI linearization would thus have been expected to eliminate the nonspecific amplification. Although this was not observed, linearization of the lavagederived HPV DNA was not performed under conditions that are optimal for BamHI restriction of supercoiled DNA templates. Thus, it may be possible to improve specificity further by optimizing the linearization protocol.
Our fidelity studies demonstrate that this LPCR method is comparable to previously reported PCR amplification systems. (8) The total number of base substitutions detected in all clones was 33 in 23,510 bp sequenced (-1/700). Most errors found were transitions, and most of these are likely to be polymerase errors, although some of these errors may have arisen from DNA damage. The most common type of DNA damage that occurs during incubation at high temperatures is deamination of cytosine to produce uracil. (8) Faithful replication of a template uracil by DNA polymerase will result in a C ~ T (or G ~ A) transition mutation. A second common type of DNA damage that may explain the nature of these errors is spontaneous base release resulting from hydrolysis of the N-glycosidic bond. (8) This type of damage is also seen often during incubation at high temperatures and low pH. The resulting apurinic/apyrimidinic sites in the DNA can inhibit DNA synthesis or alternatively be bypassed by the DNA FIGURE 3 Map of errors introduced during LPCR in ORFs E6, E7, and E1 (partial) of the HPV16 genome. The complete HPV16 genome was amplified, and HPV16 LPCR products were cloned as described in Materials and Methods. A total number of 29 individual clones were subjected to dideoxy sequencing of the region depicted and an assessment of LPCR fidelity performed. The number of errors in each individual clone is shown at right.
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It is possible that optimizations, (36~ including decreasing the number of cycles; lowering concentrations of dNTPs, divalent cations and primers; and altering thermal cycling parameters, can further improve the results presented in this report. Our analysis of fidelity was conducted, most probably, using LPCR products obtained from the plateau of amplification (as determined from the number of cycles used). The fidelity of this system may be different during the logarithmic phase. Additionally, because these studies were limited to amplification of 8-kb targets under specific conditions, it is not known whether differences in fidelity will be observed for longer targets or when alternative amplification conditions are employed. It is reasonable to conclude, however, that LPCR using the rTth XL system described will be generally useful for applications that previously would have tolerated the fidelity of PCR-based methods.
Cloning of LPCR products was achieved by the T/A method (37) (38) (39) 6 Amino acid sequence alignment of translated ORF L1, amino acids 311-501, from CP141 and HPV39. The alignment is numerically oriented from the first amino acid of the L1 ORF of the HPV39 genome. Asterisks (*) mark amino acid differences in the two sequences shown. Carats (^) mark conserved amino acid residues common to all genital papillomaviruses. may in some cases eliminate the need to design amplification primers that contain RE sites for subsequent use in cloning. It should be noted, however, that we observed variable success in applying this cloning method to LPCR products obtained from novel HPV genomes. We were only able to use T/A cloning successfully when a large quantity of LPCR amplicon was present as determined by EtBr staining in agarose gels. This may reflect a relatively low percentage of added 3' adenosines. It is possible that specific primer sequences affect the particular nucleotide added to the 3' termini by the rTth XL. Specific 3'-extendase activity has been reported for several other DNA polymerases. (41~ Alternatively, the addition of nucleotides to the 3' terminus of the PCR product may generally be less frequent (41~ under the selected LPCR conditions or the 3'~ S' exonuclease enzymatic activity might remove such nucleotides. Attempts were made to clone IS039 LPCR products by inactivating the rTth XL using proteinase K digestion and heat inactivation and, subsequently, adding 3' adenosines by incubating the LPCR products with Taq polymerase for 15 min at 72°C to facilitate T/A cloning. A total of SO white clones were screened, but no clones with the correct insert size were detected using this approach (data not shown). Our difficulties in cloning LPCR products using RE-based methods could also be an effect of remaining rTth DNA polymerase XL enzyme activity that could create blunt-ended products by filling the recessed 3' termini or that could act as an exonuclease to remove the protruding 3' termini created by digestion of the DNA with restriction enzymes. We have not implemented protocols to inactivate the rTth XL before RE digestion. We did, however, gel purify all RE-digested LPCR products prior to ligation attempts. Further studies are needed to determine the optimal doning conditions for LPCR products.
The application of LPCR methods to the isolation of unknown or partially characterized infectious agents represents an important biochemical tool for future investigations. In the study of HPVs, isolation of novel genomes has been limited to the use of labor-intensive cloning in plasmid or phage libraries. These techniques require the presence of relatively high copy numbers of HPV genomes. The methods described here utilize microliter quantities of clinical specimens to obtain complete HPV genomes. Using a previously determined sequence for the MY09/MY11 region of the HPV L10RF, we were able to design a strategy that (1) amplified the entire circular genome of a previously uncharacterized HPV; (2) was amenable to T/A cloning of the -8-kb genome; and (3) resulted in the ability to produce a linearized, intact HPV genome following RE digestion of the cloned genome.
It should be noted that the use of short PCR sequences to designate novel HPVs is supported by these investigations in which predicted entire novel HPV genomes were isolated using primers derived from short novel sequences. Current criteria for designation of a new HPV type requires <10% nucleotide similarity between the L1, E6, and E70RFs and any previously described HPV. Variants of HPV types are designated by <~2% difference in these sequences. (42) Fidelity studies presented in this report indicate that the expected error frequency of our LPCR method would be approximately one per 700 bases or <0.2%. On the basis of these data, LPCR products can be used to isolate and appropriately designate novel HPVs. LPCR methods represent valuable tools for future taxonomy studies of HPVs and potentially other uncharacterized infectious agents. The ability to use DNA molecules generated by LPCR methods in functional biologic assays remains to be determined.
